Repligen Corporation

145.15
3.75 (2.65%)
At close: Apr 24, 2025, 3:59 PM
142.40
-1.89%
After-hours: Apr 24, 2025, 07:52 PM EDT
2.65%
Bid 134
Market Cap 8.15B
Revenue (ttm) 627.84M
Net Income (ttm) -29.11M
EPS (ttm) -0.47
PE Ratio (ttm) -308.83
Forward PE 61.77
Analyst Buy
Ask 149
Volume 416,718
Avg. Volume (20D) 780,991
Open 141.81
Previous Close 141.40
Day's Range 140.97 - 145.82
52-Week Range 102.97 - 182.52
Beta 1.27

About RGEN

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used i...

Sector Healthcare
IPO Date Apr 29, 1986
Employees 1,778
Stock Exchange NASDAQ
Ticker Symbol RGEN
Full Company Profile

Analyst Forecast

According to 12 analyst ratings, the average rating for RGEN stock is "Buy." The 12-month stock price forecast is $180, which is an increase of 24.01% from the latest price.

Stock Forecasts

Next Earnings Release

Repligen Corporation is scheduled to release its earnings on Apr 29, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
1 month ago
-5.54%
Repligen shares are trading lower. Evercore ISI Gr... Unlock content with Pro Subscription
2 months ago
+7.92%
Repligen shares are trading higher after the company reported better-than-expected Q4 financial results